DUBLIN–(BUSINESS WIRE)–The “Food Allergy – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The “Food Allergy – Pipeline Insight, 2022” report provides comprehensive insights about 33+ companies and 33+ pipeline drugs in Food Allergy pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Food Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Food Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Companies and academics are working to assess challenges and seek opportunities that could influence Food Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Food Allergy.
Food Allergy Emerging Drugs Chapters
This segment of the Food Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Food Allergy Emerging Drugs
Omalizumab: Genentech, Inc.
Omalizumab is an investigational product, which is being developed by Genetech.Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody designed to selectively binds to human immunoglobulin E (IgE). This molecule is being developed in collaboration with Novartis. This drug is in Phase 3 stage of development for the treatment of food allergy.
CA002: Camallergy
CA002 is a biological drug, an investigational medicinal product employing whole peanut protein oral immunotherapy. CA002 targets best-in-class safety and efficacy by following a patient-centric treatment protocol. The CA002 formulation and advanced dosing protocol prioritise safety and efficacy as well as convenience for families and physicians. The specially-designed, pull-apart capsules are easy to use and formulated to ensure consistent delivery of characterised peanut proteins. CA002’s low-burden treatment protocol is family-friendly and efficient for physicians. Camallergy is preparing its lead product, CA002 for the treatment of peanut allergy, for Phase III trials to support regulatory approval in the US and Europe
Dupilumab: Regeneron
Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. It was invented using Regeneron’s proprietary VelocImmune technology. The potential uses of dupilumab is currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.
INP20: InnoUp Farma
INP20 are nanoparticles with encapsulated peanut extract as a food allergen. These nanoparticles have demonstrated to be completely innocuous in animal studies when administered by oral route. INP20 aims to be a platform to develop immunotherapeutic products to treat other food allergies.The drug is currently being developed in phase1/2 for the treatment of food allergy.
PVX108: Aravax
PVX108 comprises a mixture of peptides that represent sequences from peanut allergens which are critical for recognition by peanut-specific T cells. Unlike other peanut allergy immunotherapies, PVX108 does not contain the peanut proteins (allergens) which cause severe allergic reactions. PVX108 is being developed as a simple monthly intradermal injection to induce tolerance to peanuts and reduce the risk of severe allergic reactions upon accidental exposure.
INI2004: Inimmune
Inimmune is focused on utilizing several late-stage Toll-like receptor (TLR) agonists in immuno-oncology, food allergy, and allergic rhinitis. Currently the drug INI2004,is in Pre-Clinical stage of development for the treatment of food allergies.
Food Allergy: Therapeutic Assessment
This segment of the report provides insights about the different Food Allergy drugs segregated based on the following parameters that define the scope of the report, such as:
Major Players in Food Allergy
There are approx. 33+ key companies which are developing the therapies for Food Allergy. The companies which have their Food Allergy drug candidates in the most advanced stage, i.e. phase III include, Genetech.
Key Players
- Merck & Co
- DBV technologies
- Genentech
- Camallergy
- Regeneron Pharmaceuticals
- InnoUp Farma
- Aravax
- Inimmune
- Novartis Pharmaceuticals
- Astrazeneca
- Cour Pharmaceuticals
- Siolta Therapeutics
- Vedanta Biosciences
- Mabylon
- GI Innovation
Key Products
- Viaskin Peanut
- Omalizumab
- CA002
- Dupilumab
- DBV135
- INP20
- PVX108
- STMC-103H
- Ligelizumab
- INI2004
- Acalabrutinib
- AR201
- CNP-201
- ADP101
- VE 416
Key Topics Covered:
Introduction
Executive Summary
Food Allergy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Food Allergy – Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Omalizumab: Genentech, Inc.
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Dupilumab: Regeneron
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
INP20: InnoUp Farma
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
INI2004: Inimmune
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Food Allergy Key Companies
Food Allergy Key Products
Food Allergy – Unmet Needs
Food Allergy – Market Drivers and Barriers
Food Allergy – Future Perspectives and Conclusion
Food Allergy Analyst Views
Food Allergy Key Companies
- Merck & Co
- DBV technologies
- Genentech
- Camallergy
- Regeneron Pharmaceuticals
- InnoUp Farma
- Aravax
- Inimmune
- Novartis Pharmaceuticals
- Astrazeneca
- Cour Pharmaceuticals
- Siolta Therapeutics
- Vedanta Biosciences
- Mabylon
- GI Innovation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u5se26
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900